Since January this year, the Department of Health (DOH) continuously
appealed to the public to frequently wash hands, observe proper hygiene,
hydrate, eat nutritious food, and wear protective gears like face masks and face
shields as preventive part of measures against COVID-19.
With La Niña well on its way, creating erratic and extreme weather
patterns, many Filipinos are now even more susceptible to various infections
that may weaken one’s immune system. And as the threat of the coronavirus continues
to loom, any form of additional protection has never been as crucial.
This is usually in the form of vitamin supplements, especially Vitamin
C, a potent antioxidant that can decrease inflammation, boost one’s immune
system, and promote wound healing. While Vitamin C
can easily be found in many fruits including oranges, melons and vegetables
like bell peppers and broccoli, some people might not be getting the
recommended dosage of the vitamin.
In comes Sodium Ascorbate Rani-C, a non-acidic Vitamin C
supplement specifically manufactured to provide Filipinos the added daily
dosage they need at an affordable price and without the discomfort many get
when they take the acidic counterparts available in the market.
At only ₱4.00 per capsule, Rani-C
is one of the most affordable supplements available in the market. This ensures
that Filipinos can safeguard their and their family’s immune health without
hurting their wallets, especially during the pandemic.
To further assist Filipinos’ from the threats of the
virus and other infections, Rani-C is offering a limited edition Rani-C Defense
kit.
Available until supplies last, you may now get the
Rani-C Defense Kit, which includes one Rani-C box with 100 capsules and a free
500ml Sure-Guard 75% Ethyl Alcohol Hand Sanitizer Gel for only ₱400.00.
Head
out to any Watsons and Mercury Drug nationwide, or check out Watsons Online, and give your
family the added protection they need with Rani-C.
To
know more about Rani-C, follow https://www.facebook.com/watch/RaniC.SodiumAscorbate/ on Facebook.
0 Comments